Focus: Bayer is a 100,000-person global pharmaceutical and chemical giant headquartered in Leverkusen, Germany, with a diversified portfolio across oncology, cardiovascular, hematology, and ophthalmology. As a publicly traded company (BAYRY), it combines legacy branded drugs with emerging biotech programs across multiple therapeutic areas.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
No open roles listed right now. Follow Bayer to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Bayer
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Bayer's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Cornerstone revenue driver (34% of portfolio) with 10-year runway; guanylate cyclase stimulator in well-established indication.
Second-largest revenue contributor with 18-year LOE; AR inhibitor competing in crowded prostate cancer space with 53 clinical trials ongoing.
Mineralocorticoid receptor antagonist in high-unmet-need nephrology space; 40 clinical trials supporting broad CKD positioning.
Multi-indication kinase inhibitor facing LOE in 2032; significant pipeline development ongoing with 109 Phase 2 trials in metastatic colorectal cancer.
TRK inhibitor in precision oncology segment; 10 clinical trials supporting label expansion in rare NTRK-fusion tumors.
110 discontinued, 90 duplicate formulations not shown
+10 more products with revenue data
No open positions listed yet. Check their careers page directly.
Based on last 2 crawl cycles
Source: USCIS H-1B Employer Data Hub
Source: state DOL filings, aggregated via Big Local News
Active restructuring presents near-term career uncertainty; monitor role stability and organizational changes before committing to multi-year assignments.
Recent peer-reviewed publications with author affiliations at this company
+50 more products
+2 more
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo